Biosimilars

Brain Cancer

Breast Cancer

Business Management

CAR T-cell Therapy

COVID-19

Chronic Lymphocytic Leukemia

Colorectal Cancer

Disparities in Cancer Care

Gastrointestinal Cancer

Genitourinary Cancers

Global Oncology

Gynecologic Oncology

Head & Neck Cancers

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Mantle Cell Lymphoma

Melanoma & Skin Cancer

Multiple Myeloma

Myeloproliferative Neoplasms

Neoadjuvant HER2+

Non-Hodgkin Lymphoma

Oncology Nursing News

Ovarian Cancer

Pediatric Oncology

Precision Medicine in Oncology®

Prostate Cancer

Sarcomas/TGCT

Supportive Care

Urothelial Cancer

As more agents are evaluated either in addition to or following PD-1/PD-L1 inhibitors, more information may be learned about how best to leverage alternate biomarkers, according to Marina C. Garassino, MD.

PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC

FDA approvals in recent years have started to carve out a role for immunotherapy in the frontline treatment of patients with small cell lung cancer. 

Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC

Dr Loretta J. Nastoupil details key efficacy data from the TRANSFORM trial investigating lisocabtagene as a second-line therapy for R/R LBCL, and Dr Marc S Hoffman comments on how to decide on an appropriate treatment in the second-line setting for high-risk R/R LBCL.

Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)

Loretta J. Nastoupil, MD, reviews data from the ZUMA-7 trial investigating the use of axicabtagene ciloleucel as a second-line therapy for large b-cell lymphoma.

ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

OncologyLive

Oncology Fellows

Supplements And Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Subscribe

Print Subscription

eNewsletter

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: 

Articles

If the FDA’s Oncologic Drugs Advisory Committee meeting held on February 10, 2022, was any indication, the days of applying foreign single country or region data to support regulatory approval are gone; instead, regulatory decisions are headed toward the need for regional consistency through multiregional clinical trials, which could help the United States overcome the persistent underrepresentation of racial and ethnic minorities in drug development.


Rising Standards in Regulatory Decisions Highlight Challenges in Drug Development in Lung Cancer


Jason Harris has worked in journalism for more than 20 years, including stints at daily newspapers and niche publications for oncology and cardiology. He is a senior editor for 

 and the annual Giants of Cancer Care® album. He also contributes to the OncLive On Air and OncFellows podcasts. Email: 

The RaDaR assay successfully identified the patients with locoregionally advanced urothelial cancer most likely to benefit from treatment with ipilimumab and nivolumab in findings from the second cohort of the phase 1b/2a NABUCCO trial.

RaDaR Assay Predicts Patient Response to Immunotherapy in Stage III Bladder Cancer

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

OncClub: Join the Chat on Trending Trials in Cancer

Specialty

Authors

A. Daniel Pinheiro, MD, physician, Otolaryngology, Mercy Clinic, discusses a study looking at the determinants of cost in the treatment of patients with T1 to T3 oropharynx cancer.

Dr. Pinheiro on Determinants of Cost in the Treatment of T1-T3 Oropharynx Cancer

A. Daniel Pinheiro, MD

Articles

Latest Conference Coverage